Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #388833 on Elite Pharmaceuticals Inc (ELTP)
NASDAQ2020
10/10/23 3:33 PM
#388834 RE: rdfdr1 #388833
X 1. Adderall IR $335 Million X 2. In house marketing and distribution: Kirkov X 3. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million —4. Full ownership of Adderall XR $ 1.56 Billion —5. Generic Concerta- $1.2 BILLION —6. Generic Vyvanse- $5.3 BILLION ---7. Vigabatrin - VigPoder approved Pyros $233 Million —8. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million —9. Patented Unique ADF (w/o naltrexone)-- NDA —10. Mikah ANDA (s) —11. Undisclosed (s) —12. Antimetabolite ANDA- Methotrexate -$600 Million —13. Undisclosed Antimetabolite ANDA- $42 Million —14. Prasco/Burel Adderall agreement January 1st 2024 —15. Dexcel partnership approval by Israeli Health for European distribution